ATE253061T1 - Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide - Google Patents

Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide

Info

Publication number
ATE253061T1
ATE253061T1 AT99926680T AT99926680T ATE253061T1 AT E253061 T1 ATE253061 T1 AT E253061T1 AT 99926680 T AT99926680 T AT 99926680T AT 99926680 T AT99926680 T AT 99926680T AT E253061 T1 ATE253061 T1 AT E253061T1
Authority
AT
Austria
Prior art keywords
cancer
dicarboxamide
furan
thiophene
useful
Prior art date
Application number
AT99926680T
Other languages
English (en)
Inventor
Denis Labrecque
Serge Lamothe
Marc Courchesne
Laval Chan
Giorgio Attardo
Karen Meerovitch
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Application granted granted Critical
Publication of ATE253061T1 publication Critical patent/ATE253061T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AT99926680T 1998-06-29 1999-06-29 Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide ATE253061T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9106398P 1998-06-29 1998-06-29
PCT/IB1999/001221 WO2000000486A1 (en) 1998-06-29 1999-06-29 Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE253061T1 true ATE253061T1 (de) 2003-11-15

Family

ID=22225790

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99926680T ATE253061T1 (de) 1998-06-29 1999-06-29 Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide

Country Status (6)

Country Link
US (1) US6960594B2 (de)
EP (1) EP1091952B1 (de)
AT (1) ATE253061T1 (de)
AU (1) AU4385399A (de)
DE (1) DE69912432D1 (de)
WO (1) WO2000000486A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
WO2000075129A1 (en) 1999-06-07 2000-12-14 Shire Biochem Inc. Thiophene integrin inhibitors
DE60130910T2 (de) 2000-04-17 2008-07-10 Ucb Pharma, S.A. Enamin-derivate als zell-adhäsionsmoleküle
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
EP2363396A1 (de) * 2001-06-11 2011-09-07 Virochem Pharma Inc. Thiophenderivate als antivirale Mittel gegen Flavivirus-Infektion
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
DE60332482D1 (de) 2002-12-10 2010-06-17 Virochem Pharma Inc Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
JP5030947B2 (ja) * 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
SG176488A1 (en) * 2006-11-15 2011-12-29 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
EP2470183B1 (de) * 2009-08-26 2015-09-16 Merck Sharp & Dohme Corp. Heterocyclische amidverbindungen als proteinkinasehemmer
US8337334B2 (en) * 2009-09-14 2012-12-25 Nike, Inc. Golf balls with clusters of dimples having non-uniform dimple profiles
CN111285841A (zh) 2013-03-29 2020-06-16 雅沃科学有限责任公司 用于治疗癌症、神经障碍和纤维化病症的脂类呋喃、吡咯和噻吩化合物
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2017189865A1 (en) 2016-04-27 2017-11-02 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for use in the treatment of atrophic vaginitis
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0667773A4 (de) * 1992-10-14 1996-09-25 Merck & Co Inc Fibrinogen-rezeptor-antagonisten.
ES2185009T3 (es) * 1996-04-10 2003-04-16 Merck & Co Inc Antagonistas de alfa y beta 3'.

Also Published As

Publication number Publication date
WO2000000486A1 (en) 2000-01-06
US6960594B2 (en) 2005-11-01
EP1091952B1 (de) 2003-10-29
EP1091952A1 (de) 2001-04-18
DE69912432D1 (de) 2003-12-04
AU4385399A (en) 2000-01-17
US20020137947A1 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
DE69912432D1 (de) Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
WO2002002520A3 (en) Compounds to treat alzheimer's disease
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
JP2003524577A5 (de)
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
AU2001273094A1 (en) Compounds to treat alzheimer's disease
ATE299890T1 (de) Inhibitoren von gamma-secretase
SE0104248D0 (sv) Method of treatment
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
DE69914084D1 (de) Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE402257T1 (de) Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE211921T1 (de) Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE212845T1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
ATE262330T1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
SE0100684D0 (sv) New subject-matter
ATE293972T1 (de) Behandlung von chronischen schmerzen
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties